Filing Flows

Filing Flows › Companies › 10x Genomics › Cash flow

10x Genomics cash flow, quarter by quarter

Latest: Q3 2026 · from the cash-flow statements filed with the SEC

Free cash flow$14.9M in Q3 2026 · $93.8M over twelve months

Operating cash flow$15.8M
Capital spending−$971K
Free cash flow+$14.9M
Cash conversion cycle123 days

Analysis

In Q3 2026, 10x Genomics generated $15.8M of operating cash flow and spent $971K on capital projects, leaving free cash flow of $14.9M. That is $27.7M less than in Q3 2025 ($42.5M).

Over the twelve months to Sep 30, 2026, operating cash flow was $99.7M; the largest uses were other financing ($8.7M), capital spending ($5.9M), other investing ($5.4M); besides operations, cash came from shares issued ($14.1M); the cash balance rose by $93.5M.

Operating cash flow was $15.8M against net income of −$19.4M. The largest differences: stock-based pay +$23.1M, employee-related liabilities +$14.9M, inventory −$12.2M.

Its cash conversion cycle was 123 days (receivables 32 + inventory 143 − payables 52).

Free cash flow

10x Genomics: free cash flow by quarter10x Genomics: free cash flow by quarter−$9.5MQ4 2024$32.5MQ1 2025$16.1MQ2 2025$42.5MQ3 2025$39.0MQ4 2025$24.5MQ1 2026$15.4MQ2 2026$14.9MQ3 2026
Operating cash flow less capital spending.
10x Genomics: operating cash flow against capital spending10x Genomics: operating cash flow against capital spendingOperating cash flowCapital spending−$6.7M$2.7MQ4 2024$34.4M$1.9MQ1 2025$17.7M$1.6MQ2 2025$43.2M$687KQ3 2025$40.8M$1.8MQ4 2025$26.1M$1.6MQ1 2026$17.0M$1.6MQ2 2026$15.8M$971KQ3 2026
Latest (Q3 2026): Operating cash flow $15.8M, Capital spending $971K.

Capital allocation, year by year

10x Genomics: where the cash came from (up) and went (down), by fiscal year10x Genomics: where the cash came from (up) and went (down), by fiscal yearOperating cash flowShares issuedCapital spendingAcquisitionsFY2021: Operating cash flow −$21.4MFY2021: Shares issued $40.3MFY2021: Capital spending −$101MFY2021: Acquisitions −$5.5M$40.3MFY2021FY2022: Operating cash flow −$33.6MFY2022: Shares issued $21.2MFY2022: Capital spending −$132MFY2022: Acquisitions −$4.0M$21.2MFY2022FY2023: Operating cash flow −$15.2MFY2023: Shares issued $19.5MFY2023: Capital spending −$48.6M$19.5MFY2023FY2024: Operating cash flow $6.7MFY2024: Shares issued $10.9MFY2024: Capital spending −$12.4M$17.6MFY2024FY2025: Operating cash flow $136MFY2025: Shares issued $6.8MFY2025: Capital spending −$5.9M$143MFY2025
Over these 5 years operating cash flow totalled $72.5M; the largest uses were capital spending ($300M) and operating cash flow ($70.2M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$576M
Debtnone
Net cash$576M

10x Genomics funds itself: free cash flow was $93.8M over the last twelve months, with $576M of cash and investments and no debt on the balance sheet.

Where the cash came from and went

10x Genomics: sources (+) and uses (−) of cash, Q3 202610x Genomics: sources (+) and uses (−) of cash, Q3 2026Cash drawn (+) / kept (−)−$23.7MOperating cash flow$15.8MShares issued$8.5MCapital spending−$971KOther investing$468KExchange rates−$181K
10x Genomics: sources (+) and uses (−) of cash, TTM to Q3 202610x Genomics: sources (+) and uses (−) of cash, TTM to Q3 2026Operating cash flow$99.7MCash drawn (+) / kept (−)−$93.5MShares issued$14.1MOther financing−$8.7MCapital spending−$5.9MOther investing−$5.4MExchange rates−$239K

From profit to cash

10x Genomics: net income to operating cash flow, Q3 202610x Genomics: net income to operating cash flow, Q3 2026Net income−$19.4MDepreciation & amortization$9.5MStock-based pay$23.1MReceivables−$8.2MInventory−$12.2MPayables$873KEmployee-related liabilities$14.9MDeferred revenue−$1.8MPrepaid and other assets−$1.2MOther liabilities−$59KOperating cash flow$15.8M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q3 20263214352123
Q2 20262612545106
Q1 20262611130106
Q4 20252510327101
Q3 20252912432120
Q2 20252713725139
Q1 20254114421164
Q4 20244815133165

Every quarter

QuarterOperating cash flowCapital spendingShares issuedCash drawn (+) / kept (−)Free cash flow
Q3 2026$15.8M−$971K$8.5M−$23.7M$14.9M
Q2 2026$17.0M−$1.6M$3.0M−$12.2M$15.4M
Q1 2026$26.1M−$1.6M$273K−$16.3M$24.5M
Q4 2025$40.8M−$1.8M$2.2M−$41.3M$39.0M
Q3 2025$43.2M−$687K$617K−$35.0M$42.5M
Q2 2025$17.7M−$1.6M$3.5M−$20.7M$16.1M
Q1 2025$34.4M−$1.9M$422K−$33.0M$32.5M
Q4 2024−$6.7M−$2.7M$4.5M$54.1M−$9.5M

10x Genomics: income statement and cash flow

10x Genomics, Q3 2026: revenue $151M (+1% year over year), operating margin -10.7%. The chart follows the revenue to costs, profit and cash.

10x Genomics: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.